January 29, 2018 / 6:06 AM / in 24 days

BRIEF-Santhera Pharmaceuticals Holding 2017 Revenues From Sales Of Raxone Up At CHF 22.9 Million

Jan 29 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG :

* INCREASE OF 21% YOY IN FY NET REVENUES TO CHF 22.9 MILLION (2016: CHF 19.0 MILLION) FROM SALES OF RAXONE

* FOR 2017, SANTHERA ANTICIPATES A NET RESULT OF CHF -50 TO -55 MILLION.

* FOR 2018 EXPECTS NET SALES OF RAXONE FOR CURRENTLY APPROVED INDICATION LHON TO REACH CHF 28 TO 30 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below